Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Results from the TRIUMPH-4 trial, published in December 2025, showed participants with obesity and knee osteoarthritis taking retatrutide 12mg lost an average of 28.7% of their body weight at 68 weeks
You should notice improved training performance, particularly on compound lifts, and better recovery between sessions
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) not yet approved by the MHRA or EMA as of 2025
Contact your insurance provider to verify which tier Zepbound is in and what your monthly copay will be
The one bright spot in the clinical data is safety
Stay physically active Physical activity is an integral part of any weight loss plan, and Zepbound works best when combined with a reduced-calorie diet and regular exercise
US$ 21.13
US$ 23.25
US$ 22.52
US$ 21.52
